As of 1st January 2019, the Australian Government has approved the use of Crizotinib in non-small cell lung cancer with a ROS1 mutation. “The drug may stop or slow the growth of Stage IIIB (locally advanced) or Stage IV (metastatic)
Read moreUPDATE: Crizotinib now approved on PBS for ROS1 mutation in Lung Cancer!




